Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;11(5):1999-2015.
doi: 10.1007/s40121-022-00681-1. Epub 2022 Sep 4.

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

Venkateshan S Prativadibhayankaram  1 , Lawrence Soon-U Lee  2 , David Lye  2   3   4 , Xu Xiaoying  2 , Ranjani Nellore  1 , Vishal Pendharkar  1 , Hannes Hentze  1 , Siyu Guan  5 , Benjamin J Ayers  5 , Shirley G K Seah  6 , De Hoe Chye  6 , Najwa S N Talib  7 , Nivashini Kaliaperumal  7 , Wei Yee Ong  7 , Zi Xin Wong  7 , Veonice B Au  7 , Anshula Alok  7 , John E Connolly  7   8 , Jerome D Boyd-Kirkup  5 , Piers J Ingram  5 , Brendon J Hanson  5 , Kantharaj Ethirajulu  1 , Damian O'Connell  1 , Conrad E Z Chan  9   10
Affiliations

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

Venkateshan S Prativadibhayankaram et al. Infect Dis Ther. 2022 Oct.

Abstract

Introduction: AOD01 is a novel, fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody that was developed as a therapeutic against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). This first-in-human study assessed safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AOD01 in healthy volunteers.

Methods: Intravenous doses of AOD01 were evaluated in escalating cohorts [four single-dose cohorts (2, 5, 10, and 20 mg/kg) and one two-dose cohort (two doses of 20 mg/kg, 24 h apart)].

Results: Twenty-three subjects were randomized to receive AOD01 or a placebo in blinded fashion. A total of 34 treatment-emergent adverse events (TEAEs) were reported; all were mild in severity. Related events (headache and diarrhea) were reported in one subject each. No event of infusion reactions, serious adverse event (SAE), or discontinuation due to AE were reported. The changes in laboratory parameters, vital signs, and electrocardiograms were minimal. Dose-related exposure was seen from doses 2 to 20 mg/kg as confirmed by Cmax and AUC0-tlast. The median Tmax was 1.5-3 h. Clearance was dose independent. Study results revealed long half-lives (163-465 h). Antidrug antibodies (ADA) to AOD01 were not detected among subjects, except in one subject of the two-dose cohort on day 92. Sustained ex vivo neutralization of SARS-CoV-2 was recorded until day 29 with single doses from 2 to 20 mg/kg and until day 43 with two doses of 20 mg/kg.

Conclusions: AOD01 was safe and well tolerated, demonstrated dose-related PK, non-immunogenic status, and sustained ex vivo neutralization of SARS-CoV-2 after single intravenous dose ranging from 2 to 20 mg/kg and two doses of 20 mg/kg and show good potential for treatment of SARS-CoV-2 infection. (Health Sciences Authority identifier number CTA2000119).

Keywords: AOD01; Antidrug antibodies; Neutralization antibody; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean serum AOD01 concentration versus time profiles by dose. a Single-dose cohort. b Two-dose cohort
Fig. 2
Fig. 2
Individual and mean AOD01 pharmacokinetic parameters versus dose
Fig. 3
Fig. 3
Scatter plot of normalized RNA Tempus counts by time point
See this image and copyright information in PMC

References

    1. WHO. Weekly epidemiological update on COVID-19. 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on.... Accessed 25 Jan 2022.
    1. Chan CEZ, Seah SGK, Chye DH, et al. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS ONE. 2021;16:e0253487. doi: 10.1371/journal.pone.0253487. - DOI - PMC - PubMed
    1. Benani A, Ben MS. Mechanisms underlying potential therapeutic approaches for COVID-19. Front Immunol. 2020;11:1841. doi: 10.3389/fimmu.2020.01841. - DOI - PMC - PubMed
    1. Gaudinski MR, Coates EE, Novik L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019;393:889–898. doi: 10.1016/S0140-6736(19)30036-4. - DOI - PMC - PubMed
    1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. - DOI - PMC - PubMed